Skip to search formSkip to main contentSkip to account menu

CR 1505

Known as: CR-1505 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
SummaryCholecystokinin (CCK)-receptor antagonists have been reported to inhibit the effects of the hormone on the… 
1996
1996
The aim of this study was to investigate the effect of endogenous cholecystokinin (CCK) on pancreatic regeneration after acute… 
1995
1995
The effects of the intraduodenal administration of a low dose of CR-1505 for 3–7 days on the gene expression of cholecystokinin… 
1993
1993
The effects of cholecystokinin (CCK) and a CCK antagonist, loxiglumide (CR‐1505), on four freshly separated and six xenografted… 
1989
1989
The postprandial contractions of the gall bladder result from the interaction of neurohormonal factors but their relative… 
1987
1987
Loxiglumide (D,L-4-(3,4-dichloro-benzoylamino)- 5-(N-3-methoxypropyl-pentylamino)-5-oxo-pentanoic acid, CR 1505) is a derivative…